ReviewMolecular biotechnology1999
The hairpin ribozyme. Discovery, mechanism, and development for gene therapy.
Review in Molecular biotechnology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 35 citations in OpenAlex.
- A programmable ribozyme for RNA signal transduction.Nature communications · 2026Article
- Emergence of linkage between cooperative RNA replicators encoding replication and metabolic enzymes through experimental evolution.PLoS genetics · 2023Article
- Enhanced Ribozyme-Catalyzed Recombination and Oligonucleotide Assembly in Peptide-RNA Condensates.Angewandte Chemie (International ed. in English) · 2021Article
- Identification of over 200-fold more hairpin ribozymes than previously known in diverse circular RNAs.Nucleic acids research · 2021Article
- Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Chemical reviews · 2018Review
- Catalytic nucleic acid enzymes for the study and development of therapies in the central nervous system: Review Article.Gene therapy & molecular biology · 2005Article
- Single-molecule enzymology of RNA: essential functional groups impact catalysis from a distance.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections.Medicinal research reviews · 2003Review
- Human papillomavirus therapy for the prevention and treatment of cervical cancer.Current treatment options in oncology · 2003Review
- Recent advances in the elucidation of the mechanisms of action of ribozymes.Nucleic acids research · 2001Review
- RNA catalysis in frozen solutions.Doklady. Biochemistry and biophysicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hairpin ribozyme is a member of a family of small RNA endonucleases, which includes hammer-head, human hepatitis delta virus, Neurospora VS, and the lead-dependent catalytic RNAs. All these catalytic RNAs reversibly cleave the phosphodiester bond of substrate RNA to generate 5'-hydroxyl and 2',3'-cyclic phosphate termini. Whereas the reaction products from family members are similar, large structural and mechanistic differences exist. Structurally the hairpin ribozyme has two principal domains that interact to facilitate catalysis. The hairpin ribozyme uses a catalytic mechanism that does not require metals for cleavage or ligation of substrate RNA. In this regard it is presently unique among RNA catalysts. Targeting rules for cleavage of substrate have been determined and required bases for catalysis have been identified. The hairpin ribozyme has been developed and used for gene therapy and was the first ribozyme to be approved for human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.